drugset / Trial / NCT06382311
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
RandomizedSequentialQuadruple-blindPrevention
Summary
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Timeline
- Start
- 2024-04-18
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flu Pandemic mRNA | Messenger RNA (mRNA) | — | Intramuscular |
| Comparator | Influenza Virus Vaccine | Vaccine | — | Intramuscular |